Brokerages forecast that G1 Therapeutics Inc (NASDAQ:GTHX) will post ($0.72) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for G1 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.85) and the highest estimate coming in at ($0.66). G1 Therapeutics reported earnings of ($0.64) per share during the same quarter last year, which would suggest a negative year over year growth rate of 12.5%. The business is expected to announce its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that G1 Therapeutics will report full-year earnings of ($2.91) per share for the current fiscal year, with EPS estimates ranging from ($3.14) to ($2.67). For the next year, analysts expect that the business will report earnings of ($3.70) per share, with EPS estimates ranging from ($4.60) to ($3.23). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05.

GTHX has been the topic of a number of research reports. JPMorgan Chase & Co. cut G1 Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $59.00 to $41.00 in a research note on Wednesday, January 23rd. B. Riley initiated coverage on G1 Therapeutics in a research note on Thursday, February 7th. They set a “buy” rating and a $55.00 price target on the stock. BidaskClub upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, February 12th. Wedbush restated an “outperform” rating and set a $67.00 price target on shares of G1 Therapeutics in a research note on Friday, March 1st. Finally, Zacks Investment Research cut G1 Therapeutics from a “buy” rating to a “sell” rating in a research note on Tuesday, March 5th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $60.43.

A number of large investors have recently added to or reduced their stakes in GTHX. Federated Investors Inc. PA lifted its stake in G1 Therapeutics by 98.3% during the first quarter. Federated Investors Inc. PA now owns 2,039 shares of the company’s stock worth $34,000 after purchasing an additional 1,011 shares in the last quarter. Legal & General Group Plc increased its position in shares of G1 Therapeutics by 20.0% during the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after acquiring an additional 676 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of G1 Therapeutics by 1,539.2% during the first quarter. BNP Paribas Arbitrage SA now owns 5,098 shares of the company’s stock worth $85,000 after acquiring an additional 4,787 shares during the period. Meeder Asset Management Inc. increased its position in shares of G1 Therapeutics by 147.7% during the fourth quarter. Meeder Asset Management Inc. now owns 4,484 shares of the company’s stock worth $87,000 after acquiring an additional 2,674 shares during the period. Finally, NumerixS Investment Technologies Inc purchased a new stake in shares of G1 Therapeutics during the first quarter worth $98,000. Institutional investors own 73.47% of the company’s stock.

NASDAQ:GTHX traded down $0.45 during trading hours on Thursday, reaching $23.32. 273,500 shares of the stock were exchanged, compared to its average volume of 335,481. G1 Therapeutics has a twelve month low of $13.87 and a twelve month high of $69.57. The stock has a market capitalization of $890.59 million, a price-to-earnings ratio of -9.11 and a beta of 2.50.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Featured Story: Dollar Cost Averaging

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.